Fairvalue-Calculator Fairvalue-Calculator
EN DE

Hangzhou Biotest Biotech Co (688767) Fair Value & Analysis

Healthcare · CN · Market cap 5.7B CNY

Price¥35.42
Fair Value¥10.95
Upside-69.1%
Quality95/100
Evidence: High Range ¥10.95 – ¥12.49

Analysis

Hangzhou Biotest Biotech Co (688767) currently trades at ¥35.42, while our model-based Fair Value estimate is ¥10.95 — implying the stock looks roughly 69.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally. The company offers medical test products for fertility health, cardiology, oncology, inflammation, biochemistry, and various infectious diseases. It also provides veterinary test kits; fluorescence immunoassay rapid test kits; and other rapid testing kits. In addition, the company is widely utilized across various medical institutions, judicial testing systems, third-party testing organizations, Centers for Disease Control and Prevention (CDC), and private clinics. The company was founded in 2008 and is based in Hangzhou, China.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.